| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 173.35 | 11.9% |
| Total Income | 175.48 | 11.4% |
| Expenditure | 153.04 | 14.3% |
| PBT | 22.44 | 14.8% |
| Net Profit | 18.24 | 29.4% |
| OPM | 4.28% | 1.73pp |
| NPM | 9.73% | 2.73pp |
| EPS | 2.15 | 28.7% |
SMS Pharmaceuticals Reports 7% YoY Revenue Growth and 19% EBITDA Margins in Q3FY24
13 Feb 2025 · 13 Feb 2025, 02:08 am
Summary
SMS Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended December 31, 2024. The company reported a 7% YoY increase in revenue from operations, driven by strong demand and healthy growth in high-value product portfolio. Gross margins improved to 39%, up 729bps YoY, and EBITDA margins stood at 19%, up 120bps YoY. PAT rose to INR 18.24 crore, up 341bps YoY. The second phase of the backward integration project is expected to begin commercial production in March 2025, driving margin expansion from FY26 onwards.
Key Highlights
- 1
7% YoY revenue growth in Q3FY24
- 2
Improved gross margins by 729bps YoY
- 3
EBITDA margins at 19% vs 18% a year ago
- 4
PAT increased by 59% YoY
- 5
Second phase of backward integration project to begin commercial production in March 2025
Management Comments
Mr. P. Vamsi Krishna
Executive Director
We continued to see healthy volume demand for our products, supported by notable client wins across key APIs—an encouraging sign for future growth. While we are navigating pricing pressures, our focus on profitability has kept margins strong and steady. Looking ahead, we expect to end the year on a strong note. The second phase of our backward integration project, set to begin commercial production in March 2025, will drive margin expansion from FY26 onwards. Our CMO business is also set to take off and contribute to our performance. Additionally, our capacity expansion remains on track, enabling us to scale volumes across our key APIs.
Informational and educational content only. Not investment advice.